Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RED FLASH
2023-507847-13-00Phase 3Authorised
- Sponsor
- Reinier de Graaf Hospital
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxybutynin and venlafaxine in hot flash (2 arms), sponsored by Reinier de Graaf Hospital. Primary endpoint: Number and severity of hot flashes during 6-week therapy. Planned start Apr 2024; status: authorised.
02
Drugs
oxybutyninvenlafaxine
03
Conditions
hot flash
Beyond the preview
Go deeper on 2023-507847-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507847-13-00.